• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. venBio Sends Letter to Immunomedics Stockholders

    venBio Sends Letter to Immunomedics Stockholders

  2. Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results

    Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results

  3. venBio Takes Steps to Protect Rights of Immunomedics Stockholders

    venBio Takes Steps to Protect Rights of Immunomedics Stockholders

  4. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics , Inc. and Encourages Investors with Losses to Contact the Firm

    IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seattle Genetics , Inc. and Encourages Investors with Losses to Contact the Firm

  5. venBio Comments on Immunomedics Partnership Announcement

    venBio Comments on Immunomedics Partnership Announcement

  6. Primecap Odyssey Growth: Stellar Record, Low Fees

    This Gold-rated fund is a fine vehicle for new investors to gain access to the Primecap managers.

  7. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  8. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  9. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  10. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

©2017 Morningstar Advisor. All right reserved.